Correlation between level of heparinization and patency of the infarct-related coronary artery after treatment of acute myocardial infarction with alteplase (rt-PA).

[1]  D. Collen,et al.  Plasma Fibrinopeptide A Levels in Patients With Acute Myocardial Infarction Treated With Alteplase: Correlation With Concomitant Heparin, Coronary Artery Patency, and Recurrent Ischemia , 1992, Circulation.

[2]  M. Pfisterer,et al.  Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. , 1992, British heart journal.

[3]  R. Weiss,et al.  Regional myocardial metabolism of high-energy phosphates in patients with coronary artery disease. , 1991, The New England journal of medicine.

[4]  D. Collen,et al.  Requirement of heparin for arterial and venous thrombolysis with recombinant tissue-type plasminogen activator. , 1991, Blood.

[5]  J. Hsia,et al.  Comparison of heparin and aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. , 1991, The New England journal of medicine.

[6]  D. Tate,et al.  Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. , 1990, The American journal of cardiology.

[7]  J. Hsia,et al.  A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. , 1990, The New England journal of medicine.

[8]  R. W. Brower,et al.  Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency , 1989 .

[9]  A. Haeberli,et al.  Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator. , 1989, Circulation.

[10]  K. Lee,et al.  A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. , 1989, Circulation.

[11]  F. Van de Werf,et al.  Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. , 1988, BMJ.

[12]  A. M. Skene,et al.  TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION Anglo-Scandinavian Study of Early Thrombolysis (ASSET) , 1988, The Lancet.

[13]  K. Friedman,et al.  Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. , 1988, Blood.

[14]  P. Lichtlen,et al.  THROMBIN/ANTITHROMBIN-III COMPLEX LEVEL AS EARLY PREDICTOR OF REOCCLUSION AFTER SUCCESSFUL THROMBOLYSIS , 1988, The Lancet.

[15]  H. Lambertz,et al.  THROMBOLYSIS WITH TISSUE PLASMINOGEN ACTIVATOR IN ACUTE MYOCARDIAL INFARCTION: NO ADDITIONAL BENEFIT FROM IMMEDIATE PERCUTANEOUS CORONARY ANGIOPLASTY , 1988, The Lancet.

[16]  G. FitzGerald,et al.  Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. , 1988, Circulation.

[17]  P. Mombaerts,et al.  Fibrinolytic Response and Fibrin Fragment D-Dimer Levels in Patients with Deep Vein Thrombosis , 1987, Thrombosis and Haemostasis.

[18]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  LONG-TERM EFFECTS OF INTRAVENOUS THROMBOLYSIS IN ACUTE MYOCARDIAL INFARCTION: FINAL REPORT OF THE GISSI STUDY , 1987, The Lancet.

[19]  A. Jaffe,et al.  Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis. , 1987, Journal of the American College of Cardiology.

[20]  M. Mohler,et al.  D-Phe-Pro-Arg-Chloromethylketone: Its Potential Use in Inhibiting the Formation of In Vitro Artifacts in Blood Collected During Tissue-Type Plasminogen Activator Thrombolytic Therapy , 1986, Thrombosis and Haemostasis.

[21]  H. Hod,et al.  Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. , 1986, Circulation.

[22]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[23]  E. Shaw,et al.  D-Phe-Pro-ArgCH2C1-A selective affinity label for thrombin. , 1979, Thrombosis research.

[24]  W. Marget,et al.  LIPOPOLYSACCHARIDES IN CROHN'S DISEASE , 1976, The Lancet.

[25]  Barr Jb,et al.  HOME OR AWAY? , 1964, Lancet.

[26]  M. Verstraete,et al.  A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT test). , 1963, Clinica chimica acta; international journal of clinical chemistry.

[27]  Logg Mh,et al.  Para-aminosalicylic acid in tuberculosis; early results of clinical trials. , 1947 .